The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Safety and efficacy of dendritic cell immunotherapy with ad-GMCAIX in an immunocompetent preclinical tumor model of renal cell carcinoma.
Frédéric D. Birkhäuser
No relevant relationships to disclose
Richard C. Koya
No relevant relationships to disclose
Caleb Neufeld
No relevant relationships to disclose
Xuyang Lu
No relevant relationships to disclose
Ewa D. Micewicz
No relevant relationships to disclose
Thinle Chodon
No relevant relationships to disclose
Mohammad Atefi
No relevant relationships to disclose
Nils Kroeger
No relevant relationships to disclose
Edward N. Rampersaud
No relevant relationships to disclose
Gadisetti V.R. Chandramouli
No relevant relationships to disclose
Gang Li
No relevant relationships to disclose
Jonathan W. Said
No relevant relationships to disclose
Antoni Ribas
Employment or Leadership Position - Kite Pharma
Consultant or Advisory Role - Kite Pharma
William H. McBride
No relevant relationships to disclose
Fairooz F. Kabbinavar
No relevant relationships to disclose
Allan J. Pantuck
Employment or Leadership Position - Kite Pharma (U)
Consultant or Advisory Role - Kite Pharma (U)
Stock Ownership - Kite Pharma
Arie S. Belldegrun
Employment or Leadership Position - Kite Pharma (U)
Consultant or Advisory Role - Kite Pharma (U)
Stock Ownership - Kite Pharma
Joseph Riss
No relevant relationships to disclose